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Exome Sequencing Identifies PDE4D
Mutations as Another Cause of Acrodysostosis
Caroline Michot,1,10 Carine Le Goff,1,10 Alice Goldenberg,2 Avinash Abhyankar,3 Ce´line Klein,1
Esther Kinning,4 Anne-Marie Guerrot,2 Philippe Flahaut,5 Alice Duncombe,6 Genevieve Baujat,1
Stanislas Lyonnet,1 Caroline Thalassinos,7 Patrick Nitschke,8 Jean-Laurent Casanova,3,9
Martine Le Merrer,1 Arnold Munnich,1 and Vale´rie Cormier-Daire1,*
Acrodysostosis is a rare autosomal-dominant condition characterized by facial dysostosis, severe brachydactyly with cone-shaped epiph-
yses, and short stature. Moderate intellectual disability and resistance to multiple hormones might also be present. Recently, a recurrent
mutation (c.1102C>T [p.Arg368*]) in PRKAR1A has been identified in three individuals with acrodysostosis and resistance to multiple
hormones. After studying ten unrelated acrodysostosis cases, we report here de novo PRKAR1Amutations in five out of the ten individ-
uals (we found c.1102C>T [p.Arg368*] in four of the ten and c.1117T>C [p.Tyr373His] in one of the ten). We performed exome
sequencing in two of the five remaining individuals and selected phosphodiesterase 4D (PDE4D) as a candidate gene. PDE4D encodes
a class IV cyclic AMP (cAMP)-specific phosphodiesterase that regulates cAMP concentration. Exome analysis detected heterozygous
PDE4D mutations (c.673C>A [p.Pro225Thr] and c.677T>C [p.Phe226Ser]) in these two individuals. Screening of PDE4D identified
heterozygous mutations (c.568T>G [p.Ser190Ala] and c.1759A>C [p.Thr587Pro]) in two additional acrodysostosis cases. These
mutations occurred de novo in all four cases. The four individuals with PDE4D mutations shared common clinical features, namely
characteristic midface and nasal hypoplasia and moderate intellectual disability. Metabolic screening was normal in three of these
four individuals. However, resistance to parathyroid hormone and thyrotropin was consistently observed in the five cases with PRKAR1A
mutations. Finally, our study further supports the key role of the cAMP signaling pathway in skeletogenesis.Acrodysostosis (MIM 101800) is a dominantly inherited
condition consisting of (1) skeletal dysplasia characterized
by facial dysostosis with nasal hypoplasia (a depressed
nasal bridge and prominent mandible), severe brachydac-
tyly with short broad metatarsals, metacarpals, and
phalanges, cone-shaped epiphyses, advanced bone matu-
ration, spinal stenosis, and short stature; (2) resistance to
multiple hormones, including parathyroid hormone and
thyrotropin; and (3) possible neurological involvement
(moderate to mild intellectual disability).1,2 Differential
diagnoses include Albright hereditary osteodystrophy
(MIM 103580) and pseudopseudohypoparathyroidism
(MIM 612463), which are both due to loss-of-function
mutations in GNAS (a-stimulary subunit of the G protein)
(MIM 139320) and are characterized by less severe hand
and foot involvement.3
A recurrent c.1102C>T mutation in PRKAR1A (MIM
188830) has been recently identified in three cases of acro-
dysostosis with resistance to multiple hormones.4 This
gene encodes the cyclic AMP (cAMP)-dependent regula-
tory subunit of protein kinase A. The mutated subunit
impairs the protein-kinase-A response to cAMP and
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osteodystrophy.
After studying ten unrelated individuals with acrodysos-
tosis, we found PRKAR1A mutations in five out of the
ten, and we show that most of the remaining cases were
accounted for by mutations in phosphodiesterase, 4D
(PDE4D [MIM 600129]), which is also involved in cAMP
metabolism.
Ten unrelated cases were included in this study. There
was no family history, and each individual was the only
affected member in his family. Inclusion criteria were the
following: (1) the presence of severe generalized brachy-
dactyly affecting metacarpals and phalanges and associ-
ated with cone-shaped epiphyses and (2) the exclusion of
Albright hereditary osteodystrophy on the basis of normal
bioactivity of the Gs alpha subunit and normal GNAS
sequencing.
We performed a complete screening of phosphocalcic
metabolism and blood levels of creatinine, calcium,
phosphorus, thyroxin, thyrotropin, 25-hydroxyvitaminD,
1,25-dihydroxyvitaminD, parathyroid hormone (PTH),
and fibroblast growth factor 23, as well as urinary levels
of creatinine, calcium, and phosphorus. The clinicalment de Ge´ne´tique, Universite´ Paris Descartes, Sorbonne Paris Cite´, Hoˆpital
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radiological and biochemical details are summarized in
Table 1 and Figure 1.
Informed consent for participation, sample collection,
and photograph publication was obtained via protocols
approved by the Necker Hospital ethics committee.
We sequenced PRKAR1A (RefSeq accession number
NM_002734.3) by using specific primers (available upon
request) in the ten individuals. De novo PRKAR1A muta-
tions, including the recurrent mutation,4 were identified
in five out of the ten individuals (c.1102C>T [p.Arg368*]
was found in four of the five, and c.1117T>C [p.Tyr373His]
was found in one of the five) (Table 1). This missense
mutation was predicted to be damaging by PolyPhen, was
found to alter a conserved amino acid located in the cata-
lytic domain, and was not identified in alleles from 200
ethnically matched controls.
The exclusion of PRKAR1A in five acrodysostosis cases
prompted us to perform exome sequencing in two of these
five individuals. Exome capture was performed with the
SureSelect Human All Exon kit (Agilent Technologies).5
Single-end sequencing was performed on an Illumina
Genome Analyzer IIx (Illumina) and generated 72 bp
reads. For sequence alignment, variant calling, and anno-
tation, we aligned the sequences to the human genome
reference sequence (hg18 build) by using the Burrows-
Wheeler Aligner.6 Downstream processing was carried out
with the Genome Analysis Toolkit (GATK7), SAMtools,8
and Picard tools. Substitution calls were made with
GATK Unified Genotyper, whereas indel calls were made
with a GATK IndelGenotyperV2. All calls with a read
coverage %23 and a Phred-scaled SNP quality of %20
were filtered out. All the variants were annotated with an
in-house -developed annotation software system. We first
focused our analyses on nonsynonymous variants, splice-
acceptor and donor-site mutations, and coding indels
because we anticipated that synonymous variants would
be far less likely to cause disease (Table S1, available
online). We also defined variants as previously unidenti-
fied if they were absent from control populations and
from all datasets, including dbSNP129, the 1000 Genomes
Project, and in-house exome data.
On the basis of the dominant mode of inheritance of
acrodysostosis, we selected eight candidate genes that all
harbor heterozygous mutations (Table S2). Given the
involvement of PRKAR1A, a cAMP-activated protein kinase
A, in some acrodysostosis cases,4 we then only considered
gene(s) that encode proteins involved in the cAMP
signaling pathway. Therefore, we regarded PDE4D (RefSeq
accession number NM_001104631) as the best candidate
gene. Indeed,PDE4D encodes a class IVcAMP-specificphos-
phodiesterase that regulates cAMP concentration. Exome
analysis detected two PDE4D mutations (c.673C>A
[p.Pro225Thr] and c.677T>C [p.Phe226Ser]) in the two
individuals. These results were confirmed by Sanger
sequencing. Subsequent screening of the 15 PDE4D coding
exons in the three remaining cases led to the identifica-
tion of two distinct heterozygous missense mutationsThe Am(c.568T>G [p.Ser190Ala] and c.1759A>C [p.Thr587Pro])
in two additional cases. Thesemutations were not observed
in the parents of acrodysostosis-affected individuals, con-
firming that they occurred de novo.
We identified a total of four distinct heterozygous
PDE4D mutations in four individuals (Table 1). Among
them, the p.Ser190Ala substitution affected a serine
residue predicted to be phosphorylated (Uniprot database),
and the p.Thr587Pro substitution disturbed the conserved
catalytic PDEase_I domain (pfam database), which confers
the 3050-cyclic nucleotide phosphodiesterase activity. The
two remaining alterations (p.Pro225Thr and p.Phe226Ser)
affected conserved residues across species. All four muta-
tions were considered to be pathogenic by PolyPhen
and were absent from alleles in 200 ethnically matched
controls.
Here, we report PDE4D mutations in four unrelated
cases of acrodysostosis and PRKAR1A mutations in five
cases. All mutations occurred de novo, providing further
evidence that acrodysostosis has a dominant mode of
inheritance.
After we divided up the acrodysostosis-affected individ-
uals and grouped them according to the mutations they
had, our study revealed interesting genotype-phenotype
correlations. Indeed, the four individuals with PDE4D
mutations shared characteristic facial features, namely
midface hypoplasia with the canonical nasal hypoplasia
initially reported in acrodysostosis and moderate intellec-
tual disability with speech delay.1,2 The characteristic
facial dysostosis and intellectual disability were neither
observed in our individuals with PRKAR1A mutations nor
mentioned in the three previously reported cases.4 Along
the same lines, hormone resistance was observed in only
one person with PDE4D mutations—case 6 had increased
PTH levels and normal serum-phosphate levels—whereas
hormone resistance was consistently observed in individ-
uals carrying PRKAR1A mutations (all five suffered from
chronic resistance to parathyroid hormone, and four of
the five had peripheral hypothyroidism). Although our
study does not allow generalized conclusions, our find-
ings might suggest that individuals with facial dysostosis
and moderate intellectual disability should be screened
for PDE4D mutations, whereas individuals with less char-
acteristic facial features, no intellectual disability, and
hormone resistance should be screened for mutations in
PRKAR1A.
The five individuals harboring PRKAR1A mutations pre-
sented with growth retardation (<2 standard deviations
[SDs]) and decreased growth speed in late childhood
(between 7 and 13 years of age). The adult individuals
had a final height <3 SDs. Alternatively, the cases
harboring PDE4D mutations presently have normal
growth charts, but they are only 3–7 years old, and predict-
ing final adult height is therefore impossible. It is worth
noting that two out of the four PDE4D cases presented
with an acute intracranial hypertension due to sinus
thrombosis; both of these individuals required derivationerican Journal of Human Genetics 90, 740–745, April 6, 2012 741
Table 1. Clinical, Radiological, and Biochemical Data of the Ten Acrodysostosis Individuals Reported
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10
Sex female male female female female male male male male female
PRKAR1A mutation c.1102C>T c.1102C>T c.1102C>T c.1117T>C c.1102C>T     
PDE4D mutation      c.673C>A c.677T>C c.568T>G c.1759A>C 
IUGR no no no yes no yes no no no no
Postnatal growth
retardation (<2 SDs)
yes
(26 years old)
no
(8 years old)
yes
(13 years old)
yes
(22 years old)
yes
(34 years old)
no
(7 years old)
no
(4 years old)
no
(4 years old)
no
(3 years old)
yes
(38 years old)
Advanced bone age  yes yes   yes yes yes yes 
Facial dysostosis
Nasal hypoplasia no no no no no yes yes yes yes no
Depressed nasal bridge no no yes no yes yes yes yes yes no
Prominent mandible no no no no yes no no yes no yes
Peripheral dysostosis
Severe brachydactyly yes yes yes yes yes yes yes yes yes yes
Short metatarsals,
metacarpals, and
phalanges
yes yes yes yes yes yes yes yes yes yes
Cone-shaped epiphyses yes
(childhood)
yes yes yes
(childhood)
yes
(childhood)
yes yes yes yes nd
Hormonal screening
PTH (n ¼ 10–46 ng/l) 95 79 116 84 142 76 39 24 19 normal
Calcemia
(n ¼ 2.2–2.7 mmol/l)
2.35 2.47 2.4 2.57 2.37 2.18 2.47 2.4 2.5 2.38
Phosphoremia
(n ¼ 1.3–1.85 mmol/l)
1.23 1.56 1.76 nd 1.3 1.54 1.68 1.81 1.7 1.8
25-OHvitD
(n ¼ 30–80 ng/ml)
nd 26 16 nd 22 26 25 45 30 nd
1,25-diOHvitD (pg/ml) nd 39 106 65 53 nd nd nd
FGF23 (n ¼ 1–120 UI/ml) nd nd nd nd 145 90 112 171.2 60.9 nd
Free T4
(n ¼ 7.5–15 pmol/l)
8.65 hypothyroidism hypothyroidism hypothyroidism 16.71 treatment 10.4 10 14.3 17 17
TSH (n ¼ 0.34–5.6 mUI/l) 2.67 13.41 15.42 increased 0.16 2.59 2.51 3.58 2.77 1.8l
Calciuria
(n ¼ 1.5–6 mmol/l)
nd <0.2 nd nd nd 0.86 1.28 1.44 2.27 nd
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The Amsurgery and medical treatment. This observation should
prompt the careful investigation of headache complaints
in such cases. This feature, hitherto unreported in
PRKAR1A-mutation-positive individuals, might be another
distinctive characteristic specific to the clinical spectrum of
symptoms associated with PDE4D mutations. Finally,
neither PDE4D nor PRKAR1A mutations were found in
one adult individual who had characteristic skeletal
features but no hormone resistance or facial dysostosis.
One cannot exclude a molecular defect not detectable by
Sanger sequencing, but it is also conceivable that other
genes might account for acrodysostosis.
Considering PRKAR1A mutations, we confirm that
c.1102C>T is a recurrent mutation observed in seven of
the eight patients reported so far, whereas only one
missense mutation that changes a conserved amino acid
located in the cAMP binding domain has been identified.
Interestingly, the Arg388* substitution is considered
a gain-of-function mutation because it decreases protein-
kinase-A sensitivity to cAMP.4 In contrast, germ-line loss-
of-function mutations resulting in constitutive activation
of protein kinase A are responsible for Carney complex
(MIM 160980), an autosomal-dominant multiple-
neoplasia syndrome characterized by cardiac, endocrine,
cutaneous, and neural myxomatous tumors and pig-
mented lesions of the skin and mucosae.9
All mutations that we have identified in PDE4D are
heterozygous missense mutations and are presumably
responsible for impaired phosphodiesterase activity.
PDE4D belongs to the cAMP-hydrolyzing phosphodies-
terase family, which is directly involved in the rate of
cAMP degradation. Considering the crucial role of cAMP
in intracellular signaling in response to a number of
membrane-impermeable hormones, a dysregulation of
cAMP levels could be the underlying mechanism of the
acrodysostosis that results from PDE4D mutations.
The cAMP-specific PDE4 family is widely expressed, and
PDE4 isoforms have similar catalytic functions, but they
have distinct cellular functions because of differences in
specific intracellular trafficking and signaling-complex
formation.10,11 PDE4D uses different promoters to
generate multiple alternatively spliced transcript variants
(at least nine) that encode functional proteins; this might
explain the phenotype variability observed in the four re-
ported cases.
Of note, mice deficient in PDE4D exhibited delayed
growth and female infertility due to impaired ovula-
tion;12 these two symptoms have also been described in
acrodysostosis cases.13 Mouse models have also revealed
that PDE4D plays a critical role in the memory and hippo-
campal neurogenesis mediated by cAMP signaling.14
Flies deficient in the PDE4D homolog, dunce, also display
impaired central-nervous-system and reproductive func-
tion.15 All together, these data support the involvement
of PDE4D impairment in the regulation of cAMP signal-
ing, especially in growth and central-nervous-system
development.erican Journal of Human Genetics 90, 740–745, April 6, 2012 743
Figure 1. Pictures and X-Rays of Individuals 6
and 8 with PDE4D Mutations
(A1 and B1) Full-face pictures of individuals 6 (A)
and 8 (B) showing facial dysostosis with a flat
nasal bridge and nasal hypoplasia.
(A2 and B2) Profile pictures show malar hypo-
plasia.
(A3) Palmar face of right hand.
(A4 and B3) Dorsal face of hands, which are broad
and shortened.
(A5 and B4) Standard X-rays of both hands show
severe brachydactyly with short, broad meta-
carpals and phalanges, cone-shaped epiphyses
(arrows), and advanced carpal maturation.Finally, our findings further support the key role of the
cAMP signaling pathway in skeletogenesis, as previously
shown for Albright hereditary osteodystrophy due to
GNAS mutations. Ongoing studies will highlight the
specific link between PRKAR1A and PDE4D, which are
both involved in cAMP signaling and responsible for acro-
dysostosis.
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